U.S. Markets closed

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5200-0.0500 (-3.18%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5700
Open1.5500
Bid1.5000 x 4000
Ask1.5400 x 4000
Day's Range1.4650 - 1.6000
52 Week Range0.2500 - 2.4700
Volume1,296,607
Avg. Volume4,125,767
Market Cap127.088M
Beta (5Y Monthly)2.93
PE Ratio (TTM)N/A
EPS (TTM)-0.7410
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
    GlobeNewswire

    Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners

    \-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering \--– Aileron plans to use net proceeds to undertake Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated advanced non-small cell lung cancer (NSCLC) \--\-- Company plans to initiate the randomized, placebo-controlled Phase 1b NSCLC trial in second quarter 2021, marking expansion of ALRN-6924 clinical development into large cancer indication \--WATERTOWN, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN) today announced the completion of its previously announced registered direct offering of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share, for gross proceeds of $35.9 million, before deducting placement agent fees and other offering expenses payable by Aileron. Aileron is developing ALRN-6924 as a novel medicine to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy’s effects against cancer cells, a concept known as chemoprotection.New fundamental investors, including Acorn Bioventures, BVF Partners, L.P., Maven Investment Partners and Grand Oaks Capital, participated in the offering, in addition to several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC.JonesTrading Institutional Services LLC ("JonesTrading") acted as the placement agent for the offering.In addition to the $35.9 million registered direct offering, between November 12, 2020 and January 5, 2021, Aileron sold an aggregate of 9,894,519 shares of its common stock in “at the market” offerings under the Capital on DemandTM Sales Agreement with JonesTrading resulting in aggregate gross proceeds of approximately $12.7 million. Gross proceeds combined from both offerings were $48.6 million before deducting commissions and fees.With the proceeds from these transactions, Aileron believes that its cash, cash equivalents and investments will enable it to fund its current strategic plan into the second half of 2023, including the planned clinical trial of ALRN-6924 in patients with advanced non-small cell lung cancer (NSCLC).“We are thrilled to welcome Acorn Bioventures, BVF Partners and Maven Investment Partners as fundamental healthcare investors in Aileron. We believe that the participation of these funds, in addition to the continued support of key existing Aileron investors, is further validation of the potential of ALRN-6924 as an important medicine in the emerging chemoprotection field,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer of Aileron. “With the completed offering, we are well positioned to continue advancing toward our vision to bring chemoprotection to all patients with p53-mutant cancer regardless of cancer type or chemotherapy.”Dr. Aivado continued, “For decades, the medical community has largely been resigned to the sad reality that chemotherapy destroys healthy cells while destroying cancer cells. 2021 holds the promise to begin a shift in this long-held mindset with the imminent PDUFA date and potential approval of the industry’s first chemoprotective agent1 that, similar to ALRN-6924, aims to protect healthy cells from chemotherapy’s side effects. Given the increasing interest in chemoprotection and the significant unmet medical need, we believe ALRN-6924 has the potential to have an important and broad role in proactively preventing chemotherapy’s harmful effects on cancer patients.”Aileron plans to begin enrollment in a Phase 1b randomized, double-blind, placebo-controlled clinical trial of ALRN-6924 in patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin doublet chemotherapy (with or without immune checkpoint inhibitors), in the second quarter of 2021. The planned Phase 1b NSCLC trial follows Aileron’s presentation in October 2020 of clinical data from its ongoing Phase 1b clinical trial of ALRN-6924 in small cell lung cancer (SCLC) demonstrating clinical proof-of-concept that treatment with ALRN-6924 resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia in patients with p53-mutated SCLC treated with topotecan. Aileron anticipates reporting initial results from the trial late in the fourth quarter of 2021 and full results in mid-2022.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.How ALRN-6924 Is Designed to Protect Healthy Cells from Chemotherapy ALRN-6924 is being developed by Aileron as a novel chemoprotective medicine to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects.Chemotherapy preferentially acts on cells that are cycling or undergoing the process of cell division. In cancer cells, the cell cycle is unchecked, which leads to uncontrolled cell proliferation, a hallmark of cancer. Certain types of healthy cells also naturally need to cycle, such as bone marrow cells, hair follicle cells, skin cells, and cells lining the oral cavity and the gastrointestinal tract. As a result, chemotherapy preferentially targets and kills both cycling healthy cells and cycling cancer cells. This, in turn, can lead to a spectrum of chemotherapy-induced side effects, from unpleasant to life-threatening and fatal.ALRN-6924, an investigational first-in-class MDM2/MDMX dual inhibitor, is administered prior to chemotherapy to patients with p53-mutant cancers. ALRN-6924 is designed to activate normal p53 protein in patients’ healthy cells, temporarily and reversibly pausing cell cycling to selectively shield the patients’ healthy cells from chemotherapy. The protection is limited to healthy cells, as ALRN-6924 cannot work in p53-mutated cancer cells given that mutated p53 has lost its function in those cells. Therefore, cancer cells continue to cycle uninterrupted and remain fully susceptible to destruction by chemotherapy.___________________________1 The U.S. Food & Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) date of February 15, 2021 for G1 Therapeutics, Inc.’s investigational therapy trilaciclib.About Aileron TherapeuticsAileron is a clinical-stage biopharmaceutical company that is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. ALRN-6924, the company’s first-in-class MDM2/MDMX dual inhibitor activating p53, is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which the company exclusively focuses on treating patients with p53-mutated cancers. With this unique, targeted strategy, ALRN-6924 is designed to protect multiple healthy cell types throughout the body from chemotherapy while chemotherapy continues to destroy cancer cells.In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients’ quality of life and help them better tolerate chemotherapy, potentially allowing patients to complete their treatment without dose reductions or delays. Our vision is to bring chemoprotection to patients with p53-mutated cancers – approximately 50% of cancer patients – regardless of cancer type or chemotherapy. Visit us at aileronrx.com to learn more.Forward-Looking StatementsStatements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether the Company will obtain sufficient cash resources to conduct its planned clinical trials; whether initial results of clinical trials will be indicative of final results of those trials or results obtained in future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will be accepted by and warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and our operations; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form 10-Q for the period ended September 30, 2020, filed on November 12, 2020, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.Investor Contacts:Media Contact: Richard Wanstall, SVP Chief Financial OfficerLiz Melone Aileron Therapeutics617-256-6622 617-995-0900lmelone@aileronrx.com rwanstall@aileronrx.com     Hans C. Vitzthum  LifeSci Advisors, LLC.  617-430-7578  hans@lifesciadvisors.com

  • Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
    GlobeNewswire

    Aileron Therapeutics Announces $35.9 Million Registered Direct Offering

    WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about January 8, 2021, subject to the satisfaction of customary closing conditions. JonesTrading Institutional Services LLC ("JonesTrading") is acting as the placement agent for the offering.The gross proceeds to Aileron from the offering are expected to be $35.9 million, before deducting the placement agent's fees and other offering expenses payable by Aileron.Aileron intends to use the net proceeds from the public offering, together with its existing cash, cash equivalents and short-term investments, to fund clinical development of ALRN-6924 as a chemoprotective agent and for working capital and other general corporate purposes.The shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-226650) that was filed with the United States Securities and Exchange Commission ("SEC") on August 7, 2018, and declared effective by the SEC on July 15, 2019. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from JonesTrading Institutional Services LLC by calling (212) 907-5332, or by e-mailing Compliance@jonestrading.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About Aileron TherapeuticsAileron is clinical-stage biopharmaceutical company that is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. ALRN-6924, the company’s first-in-class MDM2/MDMX dual inhibitor activating p53, is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which the company exclusively focuses on treating patients with p53-mutated cancers.  Forward-Looking Statements Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, including statements about the expected closing of the offering and anticipated proceeds from the offering, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Aileron’s strategy, financing, and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions to the closing of the offering will be satisfied; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form 10-Q for the period ended September 30, 2020, filed on November 12, 2020, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.Investor Contacts:                                         Richard Wanstall, SVP Chief Financial Officer                 Aileron Therapeutics                                         617-995-0900                                                rwanstall@aileronrx.comHans C. Vitzthum LifeSci Advisors, LLC. 617-430-7578 hans@lifesciadvisors.comMedia Contact: Liz Melone 617-256-6622 lmelone@aileronrx.com

  • Medicenna vs Aileron: Which Penny Stock Could Surge Over 200%?
    TipRanks

    Medicenna vs Aileron: Which Penny Stock Could Surge Over 200%?

    2020 saw many analysts and investors explore penny stocks. These stocks, which trade at less than $5 per share, lure investors as even a small price gain can translate to a massive return in percentage. That said, due to the high level of speculation and significant risk involved, many feel that penny stock investing is akin to gambling.However, that’s not always true as there are several penny stocks which analysts believe have strong potential to grow into promising businesses. So, it is prudent for investors to understand that while the potential for gains is massive, they could possibly lose their entire investment if things go wrong.Keeping in mind the high rewards and risks involved, our focus shifted to two penny stocks, Medicenna and Aileron. Using the TipRanks Stock Comparison tool, we wanted to see which one offers a more compelling investment opportunity.Medicenna Therapeutics (MDNA)First up is clinical-stage immunotherapy company Medicenna. The Canada-based company is focused on unlocking the full potential of biological molecules called interleukins (a subset of a larger group of cellular messenger molecules called cytokines) and developing engineered interleukins called Superkines for treating cancer.The company is working on creating its therapies using interleukins from three major families: IL-2, IL-4 and IL-13. Medicenna’s lead programs are MDNA11 and MDNA55.The IL-4 empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. It has obtained fast-track and orphan drug status from the US FDA and FDA/EMA (European Medicines Agency), respectively. MDNA now intends to execute a partnership for a registration trial and commercialization of MDNA55 for recurrent GBM. (See MDNA stock analysis on TipRanks)Meanwhile, MDNA11 is a long-acting IL-2 Superkine that has been designed to preferentially bind the IL-2 beta receptor (IL-2Rβ) on immune cells and become a powerful switch for activating and proliferating the immune cells needed to fight cancer. The company anticipates that MDNA11 will be ready for the clinic in 2021.Covering Medicenna for Oppenheimer, Matthew Biegler noted that Medicenna is developing a pipeline of next-generation cytokines that are designed to be “safer and more efficacious” than Proleukin, as well as many competing new IL-2 variants.Biegler recently initiated coverage of Medicenna with a Buy rating and a price target of $12 and stated that the company’s lead product, MDNA11, has a best-in-class preclinical profile that could set it apart from a pack of competing cytokine therapies.“As a base case, we assume MDNA11 could be successfully developed in indications where Proleukin is already approved, but see many opportunities for upside. A second asset, MDNA55, has been evaluated in a Phase 2 trial in glioblastoma multiforme (GBM), where it delivered encouraging responses and prolonged survival relative to historical controls, which we think justifies further development,” added Biegler.The Street has three other analysts aside from Biegler who are bullish on Medicenna. Overall, the stock scores a Strong Buy analyst consensus and an average price target of $9.94, which implies a 158% upside potential from current levels.Aileron Therapeutics (ALRN)Aileron Therapeutics Inc is a clinical-stage biopharma company that is focused on developing a novel chemoprotective medicine to protect against multiple chemotherapy-induced side effects.The company is advancing ALRN-6924, its investigational dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types in the body from chemotherapy while ensuring that chemotherapy continues to destroy cancer cells.In October, Aileron presented positive clinical data from the trial, demonstrating clinical proof-of-concept that treatment with ALRN-6924 resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan. It plans to report additional results from the ongoing Phase 1b proof-of-concept clinical trial of ALRN-6924 in patients with SCLC receiving topotecan in the first quarter of 2021.The company now expects to initiate a Phase 1b randomized, placebo-controlled clinical trial of ALRN-6924 in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line carboplatin doublet chemotherapy in the second quarter of 2021, thus advancing ALRN-6924 clinical development into a large cancer indication. (See ALRN stock analysis on TipRanks)In a research note to investors, Jones Trading analyst Soumit Roy recently pointed to G1 Therapeutics’ TNBC trial, in which trilaciclib showed improved myelopreservation by moving from 3L (third-line) to 1L (first-line) SCLC. Roy expects to see a similar degree of clinical improvement in Aileron’s ALRN-6924 as it migrates from 2L/3L in SCLC to 1L NSCLC.Roy noted, “Latest data set presented at this Triple meeting is from - 24h dosing schedule, and allowing for ALRN-6924 administration 6h prior to chemo infusion could significantly help with the adoption rate. We would like to see if there is any additional protection from severe neutropenia at -6h dosing schedule.”The 5-star analyst reiterated a Buy rating on Aileron with a $5 price target given “the risk/benefit at current low implied valuation.”Overall, Aileron scores a Strong Buy analyst consensus based on 4 unanimous Buys. Shares have risen a staggering 85% year-to-date and the average price target of $4 indicates a major upside potential of 277% from current levels.ConclusionBoth Medicenna and Aileron are working on promising therapies in the field of oncology. These companies are expected to report additional favorable data on their lead candidates in the coming year. Based on higher upside potential, Aileron looks to be the better pick among the two penny stocks. That said, a word of caution for investors would be to consider the high risk involved in penny stock investing.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment